Citation for published version (APA):
Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers

Nicholas J. Ashton¹,²,³,⁴, Marc Suárez-Calvet¹,⁵,⁶, Amanda Heslegrave⁷,⁸, Abdul Hye³,⁴, Cristina Razquin⁹,¹⁰,¹¹, Pau Pastor¹²,¹³, Raquel Sanchez-Valle¹⁴, José L. Molinuevo⁵,¹⁴, Pieter Jelle Visser¹⁵,¹⁶, Kaj Blennow¹,¹⁷, Angela K. Hodges³,⁴*, Henrik Zetterberg¹,⁷,⁸,¹⁷*

*These authors contributed equally

¹Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; ²Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; ³King’s College London, Institute of Psychiatry, Psychology & Neuroscience, London, UK; ⁴NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK; ⁵Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation. Barcelona, Catalonia, Spain; ⁶Department of Neurology, Hospital del Mar, Barcelona, Catalonia, Spain; ⁷Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; ⁸UK Dementia Research Institute at UCL, London, UK; ⁹Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain; ¹⁰Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain; ¹¹CIBER and Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain; ¹²Fundació Docència i Recerca Mútua Terrassa, University Hospital Mútua de Terrassa, Terrassa, 08221, Barcelona, Spain; ¹³Movement Disorders Unit, Department of Neurology, University Hospital Mútua de Terrassa, Terrassa, 08222, Barcelona, Spain; ¹⁴Alzheimer's Disease and Other Cognitive Disorders Unit,
Neurology Service, Hospital Clínic, Barcelona, Spain; 

August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; 

Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, the Netherlands; 

Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands; 

Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

Corresponding author: Dr. Nicholas James Ashton

Address: Department of Psychiatry and Neurochemistry, Sahlgrenska University Hospital, Blå stråket 15, 3rd floor, Gothenburg, Sweden

Email: nicholas.ashton@gu.se
Abstract

Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer’s disease (AD) can be replicated in blood, e.g., amyloid-beta peptides (Aβ42 & Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomarkers reflecting central nervous system pathophysiology and should be fully explored for biomarkers that show promise in CSF. Recently, soluble fragments of the triggering receptor expressed on myeloid cells 2 (sTREM2) protein in CSF have been reported to be increased in prodromal AD and also in individuals with TREM2 rare genetic variants that increase the likelihood of developing dementia. In this study, we measured the levels of plasma sTREM2 and plasma NFL in 48 confirmed TREM2 rare variants carriers and 49 non-carriers. Our results indicate that there are no changes in plasma sTREM2 and NFL between TREM2 rare variants carriers and non-carriers. Furthermore, plasma sTREM2 is not different between healthy controls, mild cognitive impairment (MCI) or AD. In conclusion, plasma sTREM2 does not mimic the recent changes found in CSF sTREM2.

Key words

Alzheimer’s disease, sTREM2, blood, biomarkers, neurofilament light chain
Introduction

There has been considerable progress in the search for blood-based biomarkers able to capture the clinical course and underlying pathophysiology of Alzheimer’s disease (AD), for review see (1). Reduced plasma Aβ42/Aβ40 ratio (2-4) and increased neurofilament light chain (NFL) (5-7) are becoming consistently reported in AD and, encouragingly, these findings mimic the more established observations seen in cerebrospinal fluid (CSF) (8). NFL is not a specific biomarker for AD (9). Increases are observed in a number of neurodegenerative disorders (10-12), owing to its global reflection of axonal injury or degeneration. Yet, translating other co-pathology markers of neurodegeneration from CSF to blood has been less successful. For example, plasma total tau (T-tau) increases in AD (13) but it seems to have limited clinical utility and phosphorylated form of tau (P-tau) has proven difficult to establish as a reliable measure in blood despite recent promise (14). Likewise, TDP-43 (15), alpha-synuclein (16) and the post-synaptic dendritic biomarker, neurogranin (17), all have substantial and specific peripheral expression but levels appear to be unrelated to changes in the central nervous system.

The triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune receptor that guides essential functions of microglia. Rare variants in TREM2 strongly increase the likelihood of developing AD, frontotemporal dementia (FTD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) (18-23). TREM2 is a type-1 transmembrane protein and its ectodomain is shed at the plasma membrane by ADAM family proteases C-terminal at histidine 157 position (24-27). The resulting soluble fragment (sTREM2) is released into the extracellular space and can be found in CSF and plasma (28, 29). Recently, the concentrations of CSF sTREM2 have been shown to be increased in early symptomatic stages of sporadic (30-34) and autosomal dominant AD patients (35). Interestingly, Aβ pathology and tau-related neurodegeneration may impact levels of CSF sTREM2 differently (33). Moreover, it has been
shown that the concentrations of CSF sTREM2 vary between different disease-associated 
*TREM2* genetic variant carriers (32, 33).

Unlike CSF sTREM2, levels of sTREM2 in blood have been poorly investigated. In this study, 
we investigate plasma concentrations of sTREM2 in patients with AD and mild cognitive 
impairment (MCI) compared with aged-matched healthy controls. Furthermore, in a novel 
approach, we also report on blood concentrations of sTREM2 and NFL in *TREM2* rare variants 
carriers.

**Methods**

**Participants**

Samples from a total of 97 participants were used for these analyses (Table 1). The majority of 
samples (n=82) were from the longitudinal AD cohorts managed at King’s College London 
(KCL; AddNeuroMed (36), Kings Health Partners-Dementia Case Register (KHP-DCR) a UK 
clinic and population based study (37) and the MRC AD Biomarker study (38)). Further 
samples were obtained from DEGESCO (n=11, Dementia Genetics Spanish Consortium (39, 
40)) and EDAR (n=4, Beta amyloid oligomers in the early diagnosis of AD and as marker for 
treatment response (41)). Informed consent for all participants was obtained according to the 
Declaration of Helsinki (1991) and protocols and procedures were approved by the relevant 
local ethical committee at each site. The cohorts as mentioned above were genetically analysed 
to identify known or novel non-synonymous variants in exon 2 of the *TREM2* gene, previously 
linked to pathogenic risk or predicted to be detrimental. Of the 48 participants identified with a 
*TREM2* pathogenic variant (*TREM2*var, Table 1), 10 were control, 10 had MCI and 28 had a 
dementia diagnosis (AD). Similar age-matched non-carrier control (n=10), MCI (n=8) and AD 
(n=31) samples were also included.
Plasma measures of sTREM2 and NFL

Plasma sTREM2 was measured using an in-house electrochemoluminescent assay on the MesoScale Discovery SECTOR imager 6000 (MesoScale Discovery (MSD) Maryland, US) using a method adapted from Kleinberger et al (29). The capture antibody was the biotinylated polyclonal goat anti-human TREM2 (0.25µg/mL R&D Systems, Minneapolis, US) and the detector antibody was monoclonal mouse anti-human TREM2 (1µg/ml Santa Cruz Biotechnology, Texas, US). A standard curve for calculations of unknowns was constructed using recombinant human TREM2 (4000 – 62.5 pg/mL, Sino Biological, Beijing, China) and plasma samples were diluted 1:4 before being assayed. For a more comprehensive description of the method please see (29). For NFL, the commercially available NF-light assay on an HD-1 Simoa instrument (Quanterix, Lexington, MA, USA) was utilized. All biochemical analyses were performed at the Institute of Neurology at University College London (UCL).

Statistical analysis

Data normality was determined by the D’Agostino-Pearson test and statistical evaluation was performed on log_{10}-transformed data. After transformation, the data followed a normal distribution. All data analysis reported has been performed on log_{10}-transformed sTREM2 and NFL but the untransformed values are shown in descriptive tables and figures. To study the association of plasma measures with demographic data a Pearson product-moment correlation was utilized for age and MMSE whereas t-test (sTREM2) or a one-way analysis of covariance (ANCOVA, NFL) for gender and APOE status. Only age was a significant predictor of plasma NFL, the subsequent analyses were therefore conducted including age as a confounder. A t-test or ANCOVA were conducted to determine clinical group differences between blood
biomarkers. ANCOVA analyses were followed by a Bonferroni corrected post hoc pairwise comparison where appropriate. A partial correlation, adjusted by age, tested the association between plasma sTREM2 and plasma NFL. Statistical analysis was performed using IBM SPSS Statistics, version 25 (Armonk, NY, USA).

Results

Forty-eight confirmed TREM2 rare variant carriers and 49 non-carriers where included in the study. The TREM2 rare variant carrier group comprised of 10 different variants: p.Q33X, p.D39N, p.R47H, p.P59L, p.R62H, p.D87N, p.T96K, p.Q691H, p.H703Y and p.L868R. The demographical characteristics of the cohort are described in Table 1. There were no differences in age between TREM2 rare variant carriers (M = 75.2, SD = 7.3) and non-carriers (M = 76.1, SD = 6.7). The inclusion of gender was very similar across groups (carriers, 26/48 female [54.2%]; non-carriers, 27/49 female [55.1%]). Finally, there was no statistically significant differences in MMSE (carriers, M = 23.1, SD = 6.4; non-carriers, M = 23.3, SD = 5.0) or clinical diagnosis between the two groups (Table 1).

In the whole cohort, plasma sTREM2 was not associated with age (r = 0.060; P = 0.562), gender (P = 0.083), APOE ε4 status (P = 0.237) or MMSE (r = -0.018; P = 0.858). There were no differences in the levels of plasma sTREM2 between TREM2 rare variant carriers (M = 7.346 ng/L, SD = 5.526 ng/L) or non-carriers (M = 8.750 ng/L, SD = 5.265 ng/L), t(95) = 1.696, P = 0.093 (Fig. 1A). There were no significant differences in plasma sTREM2 between carriers of different TREM2 rare variants (F(3, 84) = 1.68, P = 0.177, Fig 1B). Note, we only included TREM2 rare variants with >2 individuals per group in this analysis. Adding clinical diagnosis as covariate did not change the result (P = 0.171). Next, we tested whether plasma sTREM2 levels differ between clinical diagnoses, regardless of the TREM2 rare variant status, between
AD (M = 8,859 ng/L, SD = 5,951 ng/L), MCI (M = 6,204 ng/L, SD = 2,572 ng/L) and controls (M = 7,352 ng/L, SD = 5,318 ng/L). Plasma sTREM2 levels were not different between these groups (F(2, 94) = 1.84, P = 0.164, Fig 1C). Adjusting for the effect of age and gender did not change the result of sTREM2 in plasma.

As expected, plasma NFL concentrations were significantly associated with age (r = 0.202, P = 0.047). After accounting for the effect of age, plasma NFL levels were found to be associated with MMSE (r = -0.353, P = 0.0004), and tended to be higher in females (M = 25.6, SD = 13.1 ng/L) compared to males (M = 25.1, SD = 22.8 ng/L; P = 0.079). Levels were not affected by APOE ε4 status (P = 0.899). There were no differences in plasma NFL between TREM2 rare variant carriers (M = 24.6 ng/L, SD = 19.1 ng/L) and non-carriers (M = 26.1 ng/L, SD = 17.1 ng/L) (F(1, 94) = 0.505, P = 0.479, Fig 2A), after adjusting for the effect of age. Similar to plasma sTREM2, there were no differences in plasma NFL when comparing the different TREM2 rare variants (F(3, 83) = 0.113, P = 0.952, Fig 2B). This remained true when correcting for the effect of the clinical diagnosis (P = 0.633). As expected, differences in plasma NFL were observed between the three clinical groups (F(2, 93) = 4.89, P = 0.010). Bonferroni corrected post hoc pairwise comparison demonstrated that the AD group (M = 29.0 ng/L, SD = 21.6 ng/L) had significantly higher levels of NFL compared to controls (M = 18.8 ng/L, SD = 7.2 ng/L; P = 0.025) but not to MCI (M = 20.5 ng/L, SD = 8.1 ng/L; P = 0.096, Fig 2C). A further adjustment for the effect of gender did not change these NFL findings.

In the whole cohort, when correcting for age, a significant positive correlation between plasma sTREM2 and plasma NFL was observed (r = 0.245, P = 0.016). However, this correlation is driven by the symptomatic individuals (MCI and AD) as no significant association of plasma sTREM2 and plasma NFL was observed in the control group (r = 0.250, P = 0.302) but a tendency in the symptomatic group (r = 0.223, P = 0.053).
Discussion

This is the first study to have comprehensively investigated if the levels of plasma sTREM2 and an neurodegenerative marker, plasma NFL, differ between TREM2 rare variant carriers and non-carriers. Our main finding demonstrates that there are no significant differences in plasma sTREM2 and NFL between these groups. Furthermore, we also show that plasma sTREM2 does not differ between controls, MCI and AD.

While sTREM2 has been extensively studied in CSF, only a few studies have reported sTREM2 in blood. Piccio and co-workers (28) demonstrated that serum sTREM2 levels did not differ between multiple sclerosis, other inflammatory neurologic diseases and non-inflammatory controls. Kleinberger et al. (29) found no difference in plasma sTREM2 between healthy controls, AD and FTD. The lack of separation between AD and controls was then independently replicated (32). In a different approach, Ohara et al. showed that increased serum sTREM2 is associated with increased risk to develop dementia in Japanese population (42). Herein, we also demonstrate that plasma sTREM2 is not different between TREM2 rare variant carriers and non-carriers, nor with respect to clinical diagnosis. Therefore, although readily detectable, sTREM2 in blood is not useful to discriminate those people with a clinical diagnostic group, or those with a TREM2 variant associated with AD. It should be noted that sTREM2 in blood most likely has a peripheral rather than a central nervous system (CNS) origin from microglia. This is in agreement with the ubiquitous expression pattern of TREM2 at both mRNA and protein levels in Human Protein Atlas (https://www.proteinatlas.org/ENSG00000095970-TREM2/tissue). TREM2 is highly expressed in cells from a myeloid lineage, such as monocytes, macrophages, Kupffer cells or osteoclasts (43-46).

Previously, it was shown that both plasma and CSF sTREM2 were useful to detect those with homozygous TREM2 mutations (e.g. p.T66M, p.W198X, p.Q33X and p.Y38C) that lead to Nasu-Hakola disease or an FTD-like syndrome (47, 48). In these diseases, sTREM2 in blood
or CSF is almost absent, which is in line with the impaired cell surface transport and shedding that occur with these mutations (29, 49). In contrast, heterozygous TREM2 rare variant carriers have a less obvious and inconsistent pattern of CSF sTREM2. While the TREM2 p.R47H rare variant is associated with increased CSF sTREM2, other TREM2 variants (e.g. p.L211P; T96K/L211P/W191X) have been reported to be associated with decreased or unchanged levels of CSF sTREM2 (e.g. R62H) (32, 33) (Deming et al. Sci Trans Med 2019 in press). Our findings could be explained by how these rare variants differently affect the processing and shedding of TREM2. For example, individual variants are believed to impact TREM2 production (Q33X), expression or turnover at the cell surface (R47H) (29, 50), α-secretase cleavage of the extracellular soluble ectodomain (H157Y) (27, 51) and/or ligand binding (R47H, R62H, T96K, H157Y) (52-54). Surprisingly, we did not find such differences in plasma, suggesting a different regulation of TREM2 in the periphery and the CNS. We also investigated plasma NFL, but here we also found no differences between TREM2 rare variant carriers and non-carriers, even when introducing clinical diagnosis as a co-variable, suggesting that the neuronal injury is no different in AD irrespective of whether someone has a TREM2 rare variant. These findings are agreement with clinical data that find AD cases with a TREM2 p.R47H rare variant are clinically indistinguishable from other AD, albeit those with a TREM2 rare variant generally have an earlier age of onset (55). Finally, the finding that sTREM2 is associated with NFL in AD is consistent with the association of CSF sTREM2 with T-tau, another marker of neurodegeneration, and suggests that inflammatory response might be coupled to neurodegeneration (56).

This study has some limitations. Despite the remarkable number of individuals with rare variants that were included, some individual variants were represented by only very small numbers, which precluded a comparison between them. Additionally, these samples did not have the core AD CSF biomarkers to confirm diagnosis, disease stage or link analyses
individually to Tau or amyloid burden, and hence we were limited to using clinical diagnosis.

The main strengths are the fact that we used very reliable and well-established assays for both sTREM2 and NFL. The study was designed in such a way that an important total number of TREM2 rare variants were carefully matched to a control group in terms of age, gender and clinical diagnosis.

In conclusion, this study, for the first time, demonstrates that the levels of sTREM2 and NFL in plasma do not differ between TREM2 rare variants carriers and non-carriers. Furthermore, we confirm previous reports that sTREM2 is not changed in AD or MCI compared with aged-matched controls. Therefore, we conclude that, although plasma sTREM2 may be useful to detect TREM2 homozygous mutations, plasma sTREM2 is not a reliable biomarker to detect TREM2 rare variant status nor suspected AD.

**Figure legends**

**Fig 1. The concentrations of plasma sTREM2.** No change in the levels of sTREM2 between TREM2 rare variant carriers and non-carriers (A, B). A non-significant increase in sTREM2 was observed in AD patients compared to MCI and aged-matched controls (C).

**Fig 2. The concentrations of plasma NFL.** No change in the concentrations of NFL between TREM2 rare variants and non-carriers (A, B). A significant increase in NFL was observed in AD patients compared to MCI and aged-matched controls which was not influenced by TREM2 mutation status (C).
Abbreviations

AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; ANCOVA, analysis of covariance; CNS, central nervous system; CSF, cerebrospinal fluid; FTD, frontotemporal dementia; MCI, mild cognitive impairment; MMSE, mini mental state examination; MSD, MesoScale Discovery; NFL, neurofilament light chain; P-tau, phosphorylated tau; PD, Parkinson’s disease; Simoa, Single molecule array; TREM2, triggering receptor expressed on myeloid cells 2; T-tau, total tau

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Availability of data and material
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

KB has served as a consultant or at advisory boards for Alector, Alzheon, CogRx, Biogen, Lilly, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper. HZ has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by
Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg.

Funding

The study has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115976. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA (AKH and HZ), the UK Dementia Research Institute (AKH and HZ) and the Olav Thon Foundation. This study is independent research partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. NfL measurements were performed on equipment purchased through a Wellcome Trust Multi-User Equipment Grant. The plasma samples were collected with funding through the EU FP6 program (AddNeuroMed).

Authors’ contributions

N.J.A, A.K.H and H.Z. provided the initial concept and study design. A.H performed all data acquisition. N.J.A and M.S.A performed data analysis, interpreted the data and co-wrote the manuscript. All authors contributed to the content of the publication, critically reviewed and edited the manuscript.

Acknowledgements

NJA is funded by the Wallenburg Centre for Molecular and Translational. MSC is funded by the European Union’s Horizon 2020 Research and Innovation Program under the Marie Sklodowska-Curie action grant agreement No 752310. RSV acknowledges funding from Grant n1 PI160235 to RSV (ISCIII, Spain, and FEDER, EU). KB is supported by the Torsten
Söderberg Foundation, Stockholm, Sweden. HZ is a Wallenberg Academy Fellow supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931) and the UK Dementia Research Institute at UCL.


Table 1. Demographic and clinical characteristics of TREM2 rare variant carriers and non-carriers

<table>
<thead>
<tr>
<th></th>
<th>TREM2 non-carriers (n=49)</th>
<th>TREM2 rare variant carriers (n=48)</th>
<th>TREM2 rare variant carriers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>p.R47H (n=26)</td>
<td>p.T96K (n=8)</td>
</tr>
<tr>
<td>Age, years (SD)</td>
<td>76.1 (6.7)</td>
<td>75.2 (7.3)</td>
<td>73.9 (8.4)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>27/49 (55.1)</td>
<td>26/48 (54.2)</td>
<td>12 (46.2)</td>
</tr>
<tr>
<td>APOE ε4 carriers, n (%)</td>
<td>24 (68.6) a</td>
<td>21 (59.7) b</td>
<td>11</td>
</tr>
<tr>
<td>MMSE, n (SD)</td>
<td>23.3 (5.0)</td>
<td>23.1 (6.4)</td>
<td>21 (7.5)</td>
</tr>
<tr>
<td>Diagnosis, n (%)</td>
<td>AD, 31/49 (63.3)</td>
<td>AD, 28/48 (58.4)</td>
<td>18/26 (69)</td>
</tr>
<tr>
<td></td>
<td>MCI, 8/49 (16.3)</td>
<td>MCI, 10/48 (20.8)</td>
<td>4/26 (15.5)</td>
</tr>
<tr>
<td></td>
<td>Ctrl, 10/49 (20.4)</td>
<td>Ctrl, 10/48 (20.8)</td>
<td>4/26 (15.5)</td>
</tr>
<tr>
<td>sTREM2, ng/L (SD)</td>
<td>8,750 (5,265)</td>
<td>7,346 (5,526)</td>
<td>7,294 (6791)</td>
</tr>
<tr>
<td>NFL, ng/L (SD)</td>
<td>26.1 (17.1)</td>
<td>24.6 (19.1)</td>
<td>25.7 (23.8)</td>
</tr>
</tbody>
</table>